Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 25, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

POTENTIAL TREATMENT FOR PERIPAPILLARY PACHYCHOROID SYNDROME.

Alexander B Pothof¹, Pedro Fernández-Avellaneda², Francine Behar-Cohen³

¹Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands.

Retinal Cases & Brief Reports

|June 26, 2023

Summary

This summary is machine-generated.

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

GWAS Meta-analysis Identifies Novel Associated Loci and Points to Causal Tissues in Central Serous Chorioretinopathy.

medRxiv : the preprint server for health sciences·2026

Same author

Steroidome Dysregulation and Complement C4 Copy Number Variation in Men With Central Serous Chorioretinopathy.

Investigative ophthalmology & visual science·2026

Same author

Neurodegeneration and neuroprotection in retinal detachment.

Handbook of clinical neurology·2026

Same author

Cross-species transcriptomics identify mineralocorticoid receptor pathway overactivation as a central driver of ocular rosacea.

Nature communications·2026

Same author

The role of the choroidal nervous system in central serous chorioretinopathy and associated diseases.

Progress in retinal and eye research·2026

Same author

Long-Term Follow-Up of PLACE and SPECTRA Trials: Outcomes After Successful and Unsuccessful Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

American journal of ophthalmology·2026

Topical prednisolone effectively reduced intraretinal fluid in patients with peripapillary pachychoroid syndrome. This steroid treatment showed promise for managing this condition, with some patients experiencing improved vision.

Area of Science:

Ophthalmology
Retinal Diseases
Pharmacology

Background:

Peripapillary pachychoroid syndrome is characterized by fluid accumulation.
Current treatment options for intraretinal fluid in this condition are limited.

Purpose of the Study:

To evaluate the efficacy of topical prednisolone in reducing intraretinal fluid.
To assess the impact of topical prednisolone on visual acuity in peripapillary pachychoroid syndrome.

Main Methods:

A case series of 11 patients (17 eyes) with peripapillary pachychoroid syndrome.
Treatment involved topical prednisolone (Pred Forte) three times daily for 4 weeks.
Dosage was tapered in patients showing fluid reduction.

Main Results:

More Related Videos

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Published on: February 26, 2021

Iris Fixation via External Pentagram Suturing

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

Related Experiment Videos

Last Updated: Jul 25, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Published on: February 26, 2021

Iris Fixation via External Pentagram Suturing

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

All 17 eyes showed an initial reduction in intraretinal fluid after 4 weeks of treatment.
35% of patients maintained fluid reduction with a tapered dosage.
24% experienced elevated intraocular pressure; recurrence of fluid occurred upon discontinuation.

Conclusions:

Topical prednisolone demonstrated effectiveness in reducing intraretinal fluid in peripapillary pachychoroid syndrome.
The treatment may offer a viable therapeutic option for this condition.
Further research is warranted to confirm these findings and assess long-term outcomes.